Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial-Reference-Cited by-同舟云学术

Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial

Published:2020-12 Issue:12 Volume:2 Page:e743-e753
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Chung Lorinda,Spino Cathie,McLain Richard,Johnson Sindhu R,Denton Christopher P,Molitor Jerry A,Steen Virginia D,Lafyatis Robert,Simms Robert W,Kafaja Suzanne,Frech Tracy M,Hsu Vivien,Domsic Robyn T,Pope Janet E,Gordon Jessica K,Mayes Maureen D,Sandorfi Nora,Hant Faye N,Bernstein Elana J,Chatterjee Soumya,Castelino Flavia V,Ajam Ali,Allanore Yannick,Matucci-Cerinic Marco,Whitfield Michael L,Distler Oliver,Singer Ora,Young Amber,Nagaraja Vivek,Fox David A,Furst Daniel E,Khanna Dinesh

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference38 articles.

1. Systemic sclerosis;Denton;Lancet,2017

2. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort;Wu;Ann Rheum Dis,2019

3. Myeloablative autologous stem-cell transplantation for severe scleroderma;Sullivan;N Engl J Med,2018

4. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial;van Laar;JAMA,2014

5. Nintedanib for systemic sclerosis-associated interstitial lung disease;Distler;N Engl J Med,2019

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The ‘whole landscape’ of research on systemic sclerosis over the past 73 years;Autoimmunity Reviews;2024-05

2. Systemic Sclerosis;Rook's Textbook of Dermatology;2024-03-19

3. Novel and potential future therapeutic options in systemic autoimmune diseases;Frontiers in Immunology;2024-03-15

4. Emerging therapeutic targets in systemic sclerosis;Journal of Molecular Medicine;2024-02-22

5. Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies;Antibodies;2024-02-01